Xenon Pharmaceuticals Inc. XENE
Set alert
38.35 USD +0.73 +1.94%
As of Nov 3, 12:41 PM ET
37.78 Day range 38.99
33.38 52-week range 72.66
- YTD
- -14.44%
- 1 year
- -6.74%
- Open
- 38.04
- Prev close
- 37.62
- Mkt cap
- 3.71B
- Vol
- 331.48K
- Avg vol
- 1.54M
- EPS
- -4.74
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 37.78
- High
- 38.99
- Forward P/E
- -8.00
- Beta
- 0.08
- Short ratio
- 2.61
- Inst. own
- 110.45%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 45.35
- 200-d avg
- 52.37
- 1y target
- 71.75
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 71.75 +87.1% upside
Now 38.35
- Target (low)
- 46.00
- Target (mean)
- 71.75
- Target (high)
- 90.00
Ratings (0m) 18 17 buy · 1 hold · 0 sell
- Strong buy3
- Buy14
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 18
- 1 month ago 19
- 2 months ago 20
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -1.14 | -1.29 – -0.94 | -1.15 | +0.5% | 0 | 0.0% | 11 |
| Next quarter | -1.16 | -1.35 – -0.85 | -1.31 | +11.3% | 840.93K | 0.0% | 11 |
| Current year | -4.63 | -4.93 – -4.06 | -4.36 | -6.1% | 1.26M | -83.2% | 13 |
| Next year | -4.70 | -5.50 – -1.90 | -4.63 | -1.6% | 26.97M | +2045.7% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 18, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Sep 18, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Sep 18, 2026 | Deutsche Bank | Downgrade | Buy | Hold |
| Sep 18, 2026 | Needham | Maintained | Buy | Buy |
| Sep 18, 2026 | Baird | Maintained | Outperform | Outperform |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 27, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 12, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| May 8, 2026 | Needham | Maintained | Buy | Buy |
| Mar 16, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Mar 10, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Deutsche Bank | Maintained | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 9, 2026 | Needham | Maintained | Buy | Buy |
| Mar 9, 2026 | Baird | Maintained | Outperform | Outperform |
| Feb 27, 2026 | Needham | Maintained | Buy | Buy |
| Feb 27, 2026 | Wells Fargo | Maintained | Overweight | Overweight |
| Feb 24, 2026 | Wolfe Research | Initiated | — | Outperform |
| Jan 9, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Dec 11, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 18, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 4, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 4, 2025 | Wells Fargo | Maintained | Overweight | Overweight |
| Nov 4, 2025 | Needham | Reiterated | Buy | Buy |
| Oct 7, 2025 | Chardan Capital | Maintained | Buy | Buy |
| Sep 2, 2025 | RBC Capital | Reiterated | Outperform | Outperform |
| Aug 12, 2025 | Chardan Capital | Maintained | Buy | Buy |